Wuxi Biologics receives Investment Bank Analyst Rating Update
Recent headlines from China highlight that authorities there are cracking down on ‘platform businesses’ amid antitrust violations. The businesses that have felt the...
China is the world's second-largest economy behind the US. And as recent data from the World Bank highlights, China will help fuel a large part of the globe's economic...
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
|Average||103.65 (+95.20% Upside)|
|No. of Analysts||27|